Coherus Claims COVID Delays As It Axes Avastin Biosimilar Program
Ending Innovent’s Avastin Partnership ‘Unfortunate Business Decision’
Coherus BioSciences, juggling both biosimilar and novel biologic assets, has called time on its partnership with China’s Innovent Biologics for biosimilar Avastin – a year after shelving development of biosimilar Eylea.
You may also be interested in...
Coherus’ Lucentis Biosimilar Outstrips Biogen Rival One Month After Launch
One month after launching its Cimerli ranibizumab biosimilar to Lucentis, Coherus BioSciences’ management explained how it had stolen a march on the earlier introduced Byooviz product launched by Biogen/Samsung Bioepis.
Coherus Will Not Alert Filing Of Pegfilgrastim On-Body
Going toe-to-toe with Amgen on its Neulasta Onpro on-body injector device is a key strategic goal for Coherus BioSciences, although news will be kept concealed until the company’s proposed biosimilar is approved or launched.
What’s Next? Five Things To Look Out For In August
A busy August brings patent expiries, biosimilar target action dates and the potential for a major change to biosimilar prescribing guidelines in Germany.